Bernard Cantin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bernard Cantin has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Benoît Lamarche
Centre Nutrition, santé et société (NUTRISS), Institut sur la nutrition et les aliments fonctionnels (INAF), Université Laval, Québec, Canada
3 shared publications Jean-Pierre Després
3 shared publicationsGilles R Dagenais
2 shared publicationsSital Moorjani
Laval University
2 shared publications- Alexander Dick
Division of Cardiology, (including Cardiac Imaging, The National Cardiac PET Centre, The Heart Failure Program, and the Cardiac Research Methods Centre), Department of Medicine, University of Ottawa Heart Institute, 40 Ruskin Ave, Ottawa, ON K1Y 4W7, Canada
1 shared publication - Benjamin J. W. Chow
Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Canada
1 shared publication
Latest Publications
- Open Access
- 16 July 2013
- Published by Springer Nature in Trials
- Vol. 14 (1) , 218
Alternative Imaging Modalities in Ischemic Heart Failure (AIMI-HF) IMAGE HF Project I-A: study protocol for a randomized controlled trial
Background: Ischemic heart disease (IHD) is the most common cause of heart failure (HF); however, the role of revascularization in these patients is still unclear. Consensus on proper use of cardiac imaging to help determine which candidates should be considered for revascularization has been hindered by the absence of clinical studies that objectively and prospectively compare the prognostic information of each test obtained using both standard and advanced imaging. Methods/Design: This paper describes the design and methods to be used in the Alternative Imaging Modalities in Ischemic Heart Failure (AIMI-HF) multi-center trial. The primary objective is to compare the effect of HF imaging strategies on the composite clinical endpoint of cardiac death, myocardial infarction (MI), cardiac arrest and re-hospitalization for cardiac causes. In AIMI-HF, patients with HF of ischemic etiology (n = 1,261) will follow HF imaging strategy algorithms according to the question(s) asked by the physicians (for example, Is there ischemia and/or viability?), in agreement with local practices. Patients will be randomized to either standard (SPECT, Single photon emission computed tomography) imaging modalities for ischemia and/or viability or advanced imaging modalities: cardiac magnetic resonance imaging (CMR) or positron emission tomography (PET). In addition, eligible and consenting patients who could not be randomized, but were allocated to standard or advanced imaging based on clinical decisions, will be included in a registry. Discussion: AIMI-HF will be the largest randomized trial evaluating the role of standard and advanced imaging modalities in the management of ischemic cardiomyopathy and heart failure. This trial will complement the results of the Surgical Treatment for Ischemic Heart Failure (STICH) viability substudy and the PET and Recovery Following Revascularization (PARR-2) trial. The results will provide policy makers with data to support (or not) further investment in and wider dissemination of alternative ‘advanced’ imaging technologies. Trial registration: NCT01288560
- 16 July 2013
- Published by Springer Nature in Trials
- Vol. 14 (1) , 218
Open AccessAlternative Imaging Modalities in Ischemic Heart Failure (AIMI-HF) IMAGE HF Project I-A: study protocol for a randomized controlled trial
Background: Ischemic heart disease (IHD) is the most common cause of heart failure (HF); however, the role of revascularization in these patients is still unclear. Consensus on proper use of cardiac imaging to help determine which candidates should be considered for revascularization has been hindered by the absence of clinical studies that objectively and prospectively compare the prognostic information of each test obtained using both standard and advanced imaging. Methods/Design: This paper describes the design and methods to be used in the Alternative Imaging Modalities in Ischemic Heart Failure (AIMI-HF) multi-center trial. The primary objective is to compare the effect of HF imaging strategies on the composite clinical endpoint of cardiac death, myocardial infarction (MI), cardiac arrest and re-hospitalization for cardiac causes. In AIMI-HF, patients with HF of ischemic etiology (n = 1,261) will follow HF imaging strategy algorithms according to the question(s) asked by the physicians (for example, Is there ischemia and/or viability?), in agreement with local practices. Patients will be randomized to either standard (SPECT, Single photon emission computed tomography) imaging modalities for ischemia and/or viability or advanced imaging modalities: cardiac magnetic resonance imaging (CMR) or positron emission tomography (PET). In addition, eligible and consenting patients who could not be randomized, but were allocated to standard or advanced imaging based on clinical decisions, will be included in a registry. Discussion: AIMI-HF will be the largest randomized trial evaluating the role of standard and advanced imaging modalities in the management of ischemic cardiomyopathy and heart failure. This trial will complement the results of the Surgical Treatment for Ischemic Heart Failure (STICH) viability substudy and the PET and Recovery Following Revascularization (PARR-2) trial. The results will provide policy makers with data to support (or not) further investment in and wider dissemination of alternative ‘advanced’ imaging technologies. Trial registration: NCT01288560
- 15 November 2003
- Published by Wolters Kluwer Health in Transplantation
- Vol. 76 (9) , 1275-1279
The impact of brain death on survival after heart transplantation: time is of the essence
It has been suggested that the modality of brain death and time from brain death until harvest impact survival and rejection after heart transplantation. Donor files from 475 adult heart-transplant recipients were examined. From these files, a total management time (time from incident leading to brain death until aortic cross clamp) was determined, and the cause of brain death was noted. Recipient characteristics, details of postoperative course, as well as survival were obtained from the Stanford University Medical Center Heart Transplantation Database. Two hundred and thirty (48.4%) donors sustained traumatic injuries, 112 (23.6%) suffered a subarachnoid hemorrhage, and 102 (21.4%) died of a gunshot wound to the head. The modality of brain death did not influence medium and long-term survival. A management time longer than 72 hours was associated with poorer outcome of the heart-transplant recipients. There were significantly more treated rejection episodes in recipients whose donor sustained traumatic injuries. Modality of brain death does not impact survival but appears to influence rejection. Increased management time is associated with adverse survival trends in heart-transplant recipients.
- 15 November 2003
- Published by Wolters Kluwer Health in Transplantation
- Vol. 76 (9) , 1275-1279
The impact of brain death on survival after heart transplantation: time is of the essence
It has been suggested that the modality of brain death and time from brain death until harvest impact survival and rejection after heart transplantation. Donor files from 475 adult heart-transplant recipients were examined. From these files, a total management time (time from incident leading to brain death until aortic cross clamp) was determined, and the cause of brain death was noted. Recipient characteristics, details of postoperative course, as well as survival were obtained from the Stanford University Medical Center Heart Transplantation Database. Two hundred and thirty (48.4%) donors sustained traumatic injuries, 112 (23.6%) suffered a subarachnoid hemorrhage, and 102 (21.4%) died of a gunshot wound to the head. The modality of brain death did not influence medium and long-term survival. A management time longer than 72 hours was associated with poorer outcome of the heart-transplant recipients. There were significantly more treated rejection episodes in recipients whose donor sustained traumatic injuries. Modality of brain death does not impact survival but appears to influence rejection. Increased management time is associated with adverse survival trends in heart-transplant recipients.
- 1 July 2003
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 22 (7) , 723-730
Post-operative conversion from cyclosporine to tacrolimus in heart transplantation: a single-center experience
- 1 July 2003
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 22 (7) , 723-730
Post-operative conversion from cyclosporine to tacrolimus in heart transplantation: a single-center experience
- 1 August 2002
- Published by Elsevier in Atherosclerosis
- Vol. 163 (2) , 261-267
Does correction of the friedewald formula using lipoprotein(a) change our estimation of ischemic heart disease risk? The Quebec Cardiovascular Study
- 1 August 2002
- Published by Elsevier in Atherosclerosis
- Vol. 163 (2) , 261-267
Does correction of the friedewald formula using lipoprotein(a) change our estimation of ischemic heart disease risk? The Quebec Cardiovascular Study
- 1 March 2002
- Published by Elsevier in The American Journal of Cardiology
- Vol. 89 (6) , 662-666
Association of fibrinogen and lipoprotein(a) as a coronary heart disease risk factor in men (The Quebec Cardiovascular Study)
- 1 March 2002
- Published by Elsevier in The American Journal of Cardiology
- Vol. 89 (6) , 662-666
Association of fibrinogen and lipoprotein(a) as a coronary heart disease risk factor in men (The Quebec Cardiovascular Study)